BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2022 9:51:35 AM | Browse: 569 | Download: 1430
 |
Received |
|
2022-04-15 13:24 |
|
Peer-Review Started |
|
2022-04-15 13:25 |
|
First Decision by Editorial Office Director |
|
2022-05-12 08:25 |
|
Return for Revision |
|
2022-05-12 08:25 |
|
Revised |
|
2022-05-27 14:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-07-29 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-08-01 04:51 |
|
Articles in Press |
|
2022-08-01 04:51 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-08-02 09:40 |
|
Publish the Manuscript Online |
|
2022-08-26 09:51 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nika De Wilde, Luisa Vonghia, Sven Francque, Thomas De Somer, Ali Bagdadi, Eva Staub, Jasper Lambrechts, Ana-Maria Bucalau, Gontran Verset and Christophe Van Steenkiste |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gontran Verset, MMed, Doctor, Doctor, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels 1070, Belgium. gontran.verset@erasme.ulb.ac.be |
| Key Words |
Advanced hepatocellular carcinoma; Systemic treatment; Immunotherapy; Nivolumab; Difficult-to-treat patients; Real-life setting |
| Core Tip |
We conducted a study on the real-world effectiveness of nivolumab (immunotherapy) in patients with advanced liver cancer who were ineligible for the standard of care or other validated treatments, including patients with impaired liver function and a poor general condition, a population that is usually not included in studies. We showed a reduction of tumor mass in 24.1% of patients, with a disappearance of tumor mass in 13.9% of patients, which is better than that reported in the literature. Furthermore, we confirmed the favorable safety profile of nivolumab. Hence, nivolumab should be considered as a valuable treatment option in selected patients who are otherwise not eligible for treatment. |
| Publish Date |
2022-08-26 09:51 |
| Citation |
De Wilde N, Vonghia L, Francque S, De Somer T, Bagdadi A, Staub E, Lambrechts J, Bucalau AM, Verset G, Van Steenkiste C. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022; 14(8): 1608-1620 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i8/1608.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i8.1608 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
